#Paraganglioma Treatment | Explore Tumblr Posts and Blogs

novaglobalhealthcare · 3 months

Text

Recent FDA-Approved Cancer Treatments and Therapies

Tisagenlecleucel (Kymriah) is the first personalized gene therapy in the United States for:

Children and adults with relapsed/refractory B-cell acute lymphoblastic leukemia (2017.)

Adults with relapsed and refractory aggressive B-cell lymphoma (2018.)

Adults with relapsed/refractory follicular lymphoma (2022.)

Tocilizumab (Actemra) treats side effects from cancer immunotherapy (2017.)

Olapirib (Lynparza) targets BRCA-mutated refractory ovarian cancer and metastatic breast cancer (2018) and early-stage breast cancer with BRCA1/2 mutations (2022.)

Iobenguane I 131 (Azedra) is the first and only treatment option for adults and children with advanced and inoperable pheochromocytomas and paragangliomas (2018.)

Gilteritinib (Xospata) is the first drug of its kind for relapsed or refractory FLT3-mutated acute myeloid leukemia (2018.)

Transoral Robotic Surgery (TORS) was approved as a technology for operating on head and neck cancers (2019.)

Selinexor (Xpovio) is the first treatment of its kind for relapsed/refractory multiple myeloma (2019.)

Entrectinib (Rozlytrek) targets NTRK-mutated cancers in children and adults and ROS1-mutated non-small-cell lung cancers in adults (2020.)

Fluoroestradiol F 18 (Cerianna) enables visual detection of recurrent breast cancer by PET scan (2020.)

Belantamab mafodotin-blmf (Blenrep) is the first antibody – drug conjugate that selectively targets and kills myeloma cells to treat relapsed/refractory multiple myeloma (2020.)

Crizotinib (Xalkori) treats relapsed/refractory ALK-mutated systemic anaplastic large-cell lymphoma as well as inflammatory ALK-mutated myofibroblastic tumors in children and young adults (2021-22.)

Belzutifan (Welirig) is the first therapy of its kind for treating von Hippel – Lindau disease-associated tumors, such as renal cell carcinoma, central nervous system hemangioblastomas and pancreatic neuroendocrine tumors (2021.)

Cabozantinib (Cabometyx) treats refractory differentiated thyroid cancer in children and adults (2021.)

Pafolacianine (Cytalux) is the first FDA-approved substance to illuminate ovarian cancer (2021) and lung cancer (2022) lesions during surgery.

Teclistamab-cqvy (Tecvayli) is the first bispecific T cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma (2022.)

Mosunetuzumab-axgb (Lunsumio) is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy (2022.)

0 notes

mothidocandart · 6 months

Text

love it when research articles have like. kind of funny titles

like go ahead and say:

"Hypertensive Crisis in a Patient With a Functioning Mesenteric Paraganglioma: Dramatic Response to Octreotide Treatment"

like chill, it wasn't their fault

0 notes

kelvindbmr · 3 years

Link

Paraganglioma is also known as pheochromocytoma is ultra-rare neuroendocrine cancers that arise from cells called paraganglia. Paraganglia cells are found near nerve cell bunches called ganglia. Most paraganglioma originate in one of the two adrenal glands located above the kidneys in the back of the upper abdomen.

#Paraganglioma Treatment Market

0 notes

amith9 · 4 years

Link

Global Paraganglioma Treatment Market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Presence of refined healthcare infrastructure and increase in special designation from the regulatory authorities are the key factors that drive the market

#Paraganglioma Treatment #Paraganglioma Treatment share #Paraganglioma Treatment size #Paraganglioma Treatment tren #Paraganglioma Treatmenttyepe #Paraganglioma Treatment report #Paraganglioma Treatment markets

0 notes

juniperpublisherscasestudies · 2 years

Text

Juniper Publishers-Open Access Journal of Case Studies

A Rare Case of Metastatic Malignant Paraganglioma : Following with F-18 FDG PET/MRI

Authored by Bedriye Koyuncu Sokmen

Abstract

Paragangliomas are rare tumors arising from undifferentiated cells of the primitive neural crest. We present a 43-year-old male patient with a glomus tumor in the left carotid space and a retroperitoneal tumor with bone metastases, with invasion of the left renal vein in the left paraaortic area posterior to the third part of the duodenum. Serum epinephrine and norepinephrine levels were high. A CT-guided trucut biopsy was performed from this lesion, and histopathological examination and immunohistochemical analyzes concluded the diagnosis of retroperitoneal paraganglioma. The tumor was judged to be secretive and inoperable; therefore, it was decided to treat it with radiotherapy and systemic chemotherapy.

Keywords: Paragangliomas; Neuroendocrine tumors; Computed tomography; Magnetic resonance imaging; PET/MRI

Introduction

Paragangliomas (PGLs) are rare neuroendocrine tumors originating from the neural crest that originate from chromaffin sympathetic tissues or parasympathetic paraganglia and can occur in a wide localization from the skull base to the pelvic floor [1]. Retroperitoneal paragangliomas are rare tumors. As only a minority of cases secrete catecholamines, they are usually non-functional tumors [2]. About 10% of paragangliomas arise outside the adrenal gland. Few cases of metastatic retroperitoneal paragangliomas have been reported in the literature [3].

Precise localization of primary and metastatic lesions is important because of the presence of critical vascular and neural structures in the vicinity of the mass. It can change the management strategy from surgery to radiation, radionuclide therapy or observation.

PET/MRI imaging systems have proven to be comparable to PET/CT in oncological imaging, and the use of MRI instead of the CT component has the theoretical advantages of lower ionizing radiation exposure, as well as improved soft tissue contrast and local tumor elaboration [4].

In this article, F-18 FDG PET/MRI findings and treatment response of a case of secretory retroperitoneal metastatic paraganglioma treated with radiotherapy and systemic chemotherapy are presented.

Case Presentation

Here, we present a rare case of retroperitoneal paraganglioma with bone metastases in a 43-year-old male patient.

The patient with a diagnosis of left glomus tumor known for 10 years was admitted to our hospital with the development of hypertension attacks. The blood pressure values were found to be 220/110mmHg in the mean measurements. In the clinical examination, our patient had a complaint of pain in the lumbar region.The patient had no smoking history or family history of paraganglioma or other neuroendocrine tumor. In the laboratory tests of the case; Urine normetanephrine value was 3358 (68-444) microgram, Vanillyl mandelic acid (VMA) was 17.1 (0-8), CrgA value was 451ng/ml and it was found above normal measurements. Urinary metanephrine value was within the normal range. Another blood tests, including liver and renal biochemistry were normal.

On PET MRI performed in January 2021, a 2x2.5cm FDG (+) mass from a glomus tumor was observed at the level of the left internal-external carotid artery bifurcation. (suvmax : 6.8) A mass lesion of approximately 3x5.5x7.5cm in size with irregular lobulated contours with FDG uptake (SUVmax: 32.47) and evaluated in favor of hypervascular retroperitoneal paraganglioma was observed in the left paraaortic area inferior to the third part of the duodenum. The defined mass seemed to invade the posterior adjacent left renal vein and the opening of the renal vein to the inferior vena cava, and surrounded the left renal artery more than 180°.

Metastatic lesions were observed in all vertebrae with FDG (+) 3.5cm in diameter, the largest of which was located on the right peduncle of the L4 vertebra (SUVmax 21.60). In addition, multiple FDG (+) bone metastases were observed in the manibrium sterni, on the right lower ribs, and bilaterally proximal to the femur (Figure 1).

A percutaneous biopsy of the L4 vertebra under CT guidance confirmed that the lesion was a paraganglioma metastasis.The patient was diagnosed with metastatic paraganglioma and underwent palliative chemotherapy.

Radiotherapy was applied to the metastases at the level of L4 vertebra with 35Gy and for the mass in the paraaortic area 45Gy. Simultaneous 12 cycles of systemic chemotherapy were also given. In chemotherapy, cyclophosphamide, vincristine and dacarbazine (CVD) were applied. Zoledronic acid was also given. Our patient received radiotherapy between January 8 and February 11. At the end of radiotherapy, our patient's blood pressure was within normal limits. (125/80mmHg)

In the control PET MRI examination of the patient, which was performed in August 2021, the mass showing significant FDG uptake (SUVmax 27.46) in the retroperitoneum in the left paraaortic area, although there is no significant difference in size, shows metabolic minimal regression. In addition, there was metabolic regression (SUVmax 17.07) in the metastasis observed in the L4 vertebra. Mass lesion consistent with paraganglioma observed at the level of the left internal-external carotid artery bifurcation were stable (Figure 2).

Discussion

Paraganglioma is a rare tumor that usually occurs in the 3rd to 4th decades. 40% of paragangliomas produce high catecholamine levels, resulting in symptoms such as headache, palpitations, profuse sweating, and elevated urinary metanephrine or vanillylmandelic acid levels. The most common site of involvement for paraganglioma in the retroperitoneum is the organs of Zuckerkandl located anterior to the aorta at the origin of the inferior mesenteric artery [5].

Paragangliomas frequently occur with recurrence or metastasis, as 30% to 40% are hereditary and the other 15-20% carry somatic mutations in one of the more than 20 well-characterized PGL susceptibility genes [1].

Computed tomography (CT) and magnetic resonance imaging (MRI) are effective non-invasive imaging modalities for the detection and evaluation of paragangliomas. MRI has advantages over CT in better soft tissue contrast, higher intrinsic flow sensitivity, and non-ionizer [8]. Magnetic resonance imaging has proven superior to other imaging techniques in demonstrating a more accurate assessment of lesion margins and invasion of adjacent structures [6].

As it is known, Paragangliomas are hypervascular tumors with imaging features of soft tissue mass with intense contrast enhancement and “salt and pepper” appearance on MRI in conventional spin-echo sequences [7].

Diffusion-weighted imaging and ADC value measurement, which are functional imaging methods taken simultaneously in PET-MRI, are used as diagnostic or differential diagnosis tools in oncology [9].

Recently, [68Ga]-DOTATATE PET/CT has emerged as a more sensitive modality for identifying occult PGLs and metastasis by targeting somatostatin receptor 2 (SSTR2) overexpression at PGLs with greater affinity than other somatostatin receptor analogues. A new modality, PET/MR imaging systems have proven to be comparable to PET/CT in oncological imaging. The use of MRI instead of the CT component has the theoretical advantages of lower exposure to ionizing radiation, as well as improved soft tissue contrast and identification of the local tumor and surrounding structures. Some case studies showed much greater soft tissue contrast with [68Ga]-DOTATATE PET/MR compared to PET/CT in PGL patients, allowing for more accurate tumor identification resulting in changes in preoperative planning [10-12]. The prospective analysis of 8 PGL patients with [18F]-FDG PET/CT and [18F]-FDOPA PET/CT and subsequent PET/MR showed that PET/MR was superior for HNPGL, abdominopelvic PGL, and liver metastasis while equivalent to PET/CT for bone metastasis [13].

In the patient presented here, PET-MRI findings are more valuable than PET-CT in cases where the MR component is superior to CT in the detailed evaluation of the soft tissue component in the relationship of retroperitoneal paraganglioma with vascular structures, and in the detailed evaluation of the soft tissue component in bone metastasis.

Conclusion

Hybrid imaging PET/MRI examination is important in the identification of primary neoplasm as well as in the detection of distant metastases in a single session. Combined multi-parametric imaging improves patient comfort and is well suited for examining patients with hereditary syndromes and paragangliomas, especially in the pediatric population, given the lower radiation exposure compared to PET/CT as a replacement for the CT component.

To know more about Juniper Publishers please click on: https://juniperpublishers.com/manuscript-guidelines.php

For more articles in Open Access Journal of Case Studies please click on: https://juniperpublishers.com/jojcs/index.php

#Juniper Publishers in USA #Juniper Journals #Emergency Medicine #Hepatology #Obstetrics and Gynaecology #Rheumatology #transplantation medicine

0 notes

healthcare-market · 2 years

Text

Radiopharmaceutical Theranostics Market to Witness Widespread Expansion by 2031

Radiopharmaceutical Theranostics Market: Introduction

According to the report, the global radiopharmaceutical theranostics market was valued at US$ 0.84 Bn in 2020 and is projected to expand at a CAGR of 11% from 2021 to 2031. Nuclear medicine imaging is primarily based on the principle of using radioactive isotopes attached to specific molecules (i.e., radiopharmaceutical agents or radiotracers) to examine key biologic processes, including disease pathophysiology. Radiopharmaceuticals are agents used for both diagnostic and therapeutic purposes. Organizations across the world classify these differently. According to the WHO, these are categorized into ready-for-use radioactive goods, radionuclide generators, non-radioactive components (“kits”) for the production of labelled compounds containing a radioactive component, and precursors used for radiolabelling other substances prior to administration.

The radiopharmaceutical market is projected to be driven by factors such as increase in therapeutic applications, public awareness, usage of hybrid imaging, technological advancements, efficient diagnosis & treatments, emergence of new radioisotopes, and replacement of traditional equipment.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82604

Rise in Prevalence of Cancer to Drive Global Market

The significance of customized medicine has been growing rapidly, owing to a more urgent need to avoid unnecessary and expensive treatments. In radiopharmaceuticals, the theranostics approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of potential targets could help predict if a patient would benefit from a particular treatment. According to the International Agency for Research on Cancer, the global cancer burden surged to 19.3 million cases and 10 million cancer deaths in 2020. By 2040, the number of new cancer cases per year is anticipated to reach 29.5 million, with 16.4 million cancer-related deaths.

Radiopharmaceutical theranostics is becoming an increasingly essential component of cancer treatment. Radioiodine is the classic radiotheranostic agent for clinical treatment of thyroid tumors. Radiolabeled metaiodobenzylguanidine is another prominent radiotheranostic drug, which has been used for diagnostic imaging and therapy of neuroblastoma, paraganglioma, and pheochromocytoma patients.

Significant and promising advancements have been made in radiotheranostics for neuroendocrine tumors, prostate cancer, and other conditions. Few instance of radiopharmaceutical theranostics pair are 177Lu/68Ga, 111In, 223Ra/99Tc, 18NaF, 131I/123I, 124I, etc.

Radiopharmaceutical theranostics is gaining traction and will most likely be able to expand its scope to include new cancer biomarkers and indications in future. Hence, rise in the prevalence of cancer is projected to propel the demand for radiopharmaceutical theranostics over the next few years.

Request for Analysis of COVID19 Impact on Radiopharmaceutical Theranostics Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=82604

Lutetium (Lu) 177 to Dominate Global Market

In terms of radioisotope, the global radiopharmaceutical theranostics market has been classified into technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18, yttrium-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. The lutetium (Lu) 177 segment dominated the global radiopharmaceutical theranostics market in 2020 and the trend is anticipated to continue during the forecast period. The favorable nuclear characteristics as well as easy availability of high activity levels of high specific activity 177Lu are the major factors for the widespread interest in the clinical use of this radionuclide.

Oncology to Offer Lucrative Opportunities

Based on application, the global radiopharmaceutical theranostics market has been categorized into oncology, cardiology, and others. The oncology segment dominated the global radiopharmaceutical theranostics market in 2020. Most of the radioisotopes are used in oncology for diagnosis or radiation therapy. 68 Ga DOTATE and 177 Lu DOTATOC is the commonly used theranostics pair in diagnosis and treatment of neuroendocrine tumors.

High Number of Cyclotrons Facilities to Drive Global Market

In terms of source, the global radiopharmaceutical theranostics market has been bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment dominated the market in 2020. The segment is expected to expand at the highest CAGR from 2021 to 2031. The segment is likely to witness rapid growth, owing to a large number of existing cyclotron facilities across the world.

Request a Sample of Radiopharmaceutical Theranostics Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=82604

Targeted Therapeutic (Rx) to be Promising Segment

Based on approach, the global radiopharmaceutical theranostics market has been classified into targeted therapeutic (Rx) and companion diagnostic (DX). The targeted therapeutic (Rx) segment dominated the market in 2020. The segment is projected to expand at the highest CAGR from 2021 to 2031. Increasing evidence supports the efficacy and safety of targeted therapeutics, as well as an increase in overall survival.

Hospitals to be Major End Users

In terms of end user, the global radiopharmaceutical theranostics market has been divided into academic & research institutes, hospitals, and others. The hospitals segment dominated the market in 2020. The segment is anticipated to expand at the highest CAGR from 2021 to 2031. Rise in number of hospital facilities and favorable outcomes of treatment in hospitals due to the availability of a range of treatment options lead to high preference to hospitals.

North America to Lead Radiopharmaceutical Theranostics Market

The global radiopharmaceutical theranostics market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2020, followed by Europe. North America accounted for a major share of the global radiopharmaceutical theranostics market in 2020. The high prevalence of neuroendocrine tumors (NETs) drives the radiopharmaceutical theranostics market in North America. Over 12,000 people in the U.S. are diagnosed with neuroendocrine tumors each year. The sensitivity and specificity of Ga-68 and Lu-177 as a theranostics pair have been evaluated in a number of clinical trials. This factor is expected to fuel the growth of the market in the region.

Enquiry before Buying Radiopharmaceutical Theranostics Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=82604

Competition Landscape

The global radiopharmaceutical theranostics market is fragmented due to the presence of a large number of leading players. Key players operating in the global market include Nihon Medi-Physics, ITM Isotopen Technologien München AG, Advanced Accelerator Applications, Telix Pharmaceuticals, GE Healthcare, Theragnostics Ltd, NuView Life Sciences, Jubilant Pharma Limited, Lantheus Holdings, Inc., Curium Pharma, Bayer AG, and Clarity Pharmaceuticals. New product development through robust R&D activities and mergers & acquisitions are the key strategies adopted by these players to expand business in the global radiopharmaceutical theranostics market.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.co.uk/news-releases/continuous-r-amp-d-to-expand-therapeutic-use-of-platelet-rich-plasma-prp-in-regenerative-therapies-offer-profitable-opportunities-to-platelet-rich-plasma-market-players-global-market-valuation-to-reach-us-811-34-mn-by-2030-tmr-study-825481498.html

https://www.prnewswire.com/news-releases/increase-in-demand-for-new-therapies-for-effective-management-to-drive-global-menopausal-hot-flashes-treatment-market-says-tmr-301378552.html

https://www.prnewswire.com/news-releases/plant-based-vaccines-market-is-expected-to-reach-us-2-34-billion-by-2031-end-emergence-of-numerous-infectious-diseases-to-fuel-growth-of-the-market-says-tmr-301385503.html

About Us Section:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com

0 notes

strategicmarketresearch · 2 years

Link

0 notes

medsurgeindia123 · 2 years

Text

Paraganglioma Treatment in India - MedsurgeIndia

An abnormal cell growth known as a paraganglioma develops from a certain type of nerve cell that is present throughout the body. MedsurgeIndia is providing the affordable Paraganglioma Treatment in India with top surgeons.

#Paraganglioma Treatment in India

0 notes

newscheckz · 4 years

Text

Mediheal Group of Hospitals eyes modern ambulance

New Post has been published on https://newscheckz.com/mediheal-group-hospitals-eyes-modern-ambulance/

Mediheal Group of Hospitals eyes modern ambulance

Dr. S. R. Mishra: “As I look back on the years of successful development and aspirations beginning with the establishment of Mediheal Group of Hospitals, I feel both proud and excited about the future. As a progressive healthcare provider, we aim to keep expanding with new facilities and continue the momentum as one of the fastest growing healthcare groups in Africa.”

Mediheal Group of Hospitals is set to launch rapid response ambulances that will offer ambulatory and evacuation services, equipped with a modern ICU facilities that is available a round the clock.

The Mediheal Group of Hospitals; established in the year 2002 , is the leading largest healthcare service provider in East Africa with high focus on quality, cost effective & world-class healthcare, and respect for human beings.

The hospital provides an attractive and welcoming environment for patients and visitors with modern consulting rooms and in-patient services through which patients benefit from modern healthcare facilities.

The facility is redesigned around the needs of the patient to enhance the quality of care and speed up diagnosis and treatment. Mediheal Hospital & Fertility Centre is affiliated to more than 250 insurance companies and corporate clients throughout the East African region.

“We have considerable and commendable experience in the health care industry and we believe we are best equipped to provide quality healthcare services,” Assures Dr. Swarup R. Mishra, a renowned Gynaecologist and Fertility expert, internationally known for his academic, professional and managerial excellence as well a highly experienced Board of Directors, Founder and Chairman of Mediheal Mediheal Group of Hospitals.

The Group is professionally governed by highly experiences Board of Directors with various committees and sub-committees.

The Hospital offers full spectrum of integrated healthcare services from clinics to hospitals to tertiary care and a wide range of ancillary services.

Some of its services includes: A group of 10 tertiary care centers (Nairobi, Eldoret, Nakuru & Kigali), 1200+ session over 25 specialties, 400+ beds and 100+ dialysis beds, Six Magnetic Resonance Imaging (MRI) machines, Seven Computerized Tomography (CT) Scanners, Ten modern specialty-specific modular Operation Theatres, Only hospital in the region offering Pediatric Endocrinology services, a fully equipped Neurosurgery theatre, which includes CUSA, Navigation, Advanced Endoscopic systems, HEPA Filter operation theatres with laminar air flow specially equipped transplant ICUs with 0% surgical infections. excision complete removal and State of the art diagnostic and therapeutic services.

The hospital also provides medical Care for International Patients in Kenya; catering to the healthcare needs of patients travelling from different geographies like Tanzania, Rwanda, Burundi, Ethiopia, Uganda, S. Sudan, and Congo to name a few at a very affordable cost.

“We offer accessible and adequate healthcare services and making a meaningful difference in the lives of patients for better health.”

Dr. Pallavi Mishra also a founding board member of the Mediheal Group of Hospitals, is a renowned Obstetrician & Gynaecologist and has worked in the field of IVF for the past 8 years. She manages Intra, Pre, and Post ART patients actively at Mediheal Hospital & Fertility Centre.

Mediheal also boasts of renowned resident doctors in the areas of Internal Medicine, Gynaecology, Dentistry, Radiology, Ophthalmology, Cardiology and Pathology and accident & Emergency unit with a Modern Theatre, Radiology Unit, Laboratory Unit, and Cardiac and Renal Centers. In the event of emergencies, the hospital

“We attend to most medical and surgical patients including but not limited to Trauma, Neurology, Cardiac, Renal, Gynaecology and Gastroenterology. Our Intensive Care Unit (ICU) and Neonatal Intensive Care Unit (NICU), and High Dependency Unit (HDU) are unique in the North rift region.”

Doctors Plaza focuses on offering selected specialty services in a unique tech-enabled environment. It has been designed for those who seek exclusivity and comfort in healthcare. The centre delivers advanced care under the management of reputed doctors, following the world’s latest treatment protocols and medical practices.

“Additionally, our innovative approach to healthcare provision enables us to be the pioneers in the fields of Assisted Reproductive Techniques (also known as test tube babies and IVF), non -invasive pain management and cosmetic surgery, amongst others. This has enabled us over the years to effectively serve thousands of patients within Africa.”

Specializing in complex surgical interventions including transplants, we give patients comprehensive care in a plush, comfortable and infection free environment: Advanced 1.5 Tesla MRI, State of the-art HEPA Filter Theatre with Laminar Air Flow (WORLD-CLASS OT INFRASTRUCTURE) and Cubicle ICUs for transplant patients.

The Group has two facilities in Nairobi, and single ones in Eldoret, Nakuru, and Kigali; offering tertiary level, diagnostic and therapeutic services. Within these facilities; major and minor surgeries along with primary and tertiary healthcare services are attended to.

“We have pioneered many innovations and healthcare standards while attending to medical and surgical patients including but not limited to trauma, neurology, cardiac, renal, gynaecology, and gastroenterology.”

Some of the achievements the Group of Hospital has earned includes but not limited: 1000+ IVF cycles per year, Mediheal Hospitals delivered the First IVF baby in Rwanda, First laparoscopic donor nephrectomy for renal transplant in East Africa, More than 50 Renal Transplants with highest success rates in Africa.

First Thoracic paraspinal tumour confirmed to be Paraganglioma (Thoracic Pheochromocytoma) in Africa, Pioneers in the field of non-invasive pain management and cosmetic surgery, First in the region for complete removal of endoscopic transsphenoidal pituitary, Treating the case of post inflammatory cervical kyphosis with quadriplegia and respiratory distress and Rare case of dorsal dermoid tumor with tethering of dorsal cord among others.

And if still you are wondering what is so unique about Mediheal hospital from other competing hospital, then here are its exclusivity;

Unlike other private hospitals where you have to pay deposit to be admitted or attended to, Mediheal Group of Hospitals do not collect any deposit when patients get registered to be admitted. They are pioneers in IVF treatment with the highest success rate in the region.

Furthermore; one of its top celebrated Gynaecologists is available a round the clock to take care of the needs of the patients. They give their clients a range of medical covers options through its affiliations with all insurance companies and corporate clients, supported by a range of specialty doctors.

The hospitals have a dedicated team of in-house Radiologists who manage Radiology services that include MRI, CT, X-ray, Ultrasound, Mammography, ECO, and ECG. Additionally, its cutting-edge Cosmetology and Plastic Surgery department is headed by some of the world renowned specialists.

Recently, they introduced many day care procedures, innovative keyhole surgeries with minimum stay in the hospital just to mention a few.

“As a progressive healthcare provider, we aim to keep expanding with new facilities and continue the momentum as one of the fastest growing healthcare groups in Africa,” concludes Dr. S. R. Mishra

#mediheal group of hospitals

0 notes

safehomediy · 4 years

Photo

Pheochromocytoma and Paraganglioma Treatment https://ift.tt/3dKYdZN

#IFTTT #Safe Home DIY

0 notes

drmudit · 4 years

Text

Face Cancer Doctor in Delhi

Are you seeking the help of a reputed and expert neck and face doctor in Delhi? Get world-class treatment for diseases including mouth/oral/neck cancer and paraganglioma among others under the able care and supervision of Dr. Mudit Agarwal. For more details visit headneckdoctor.com

#Face Cancer Doctor in Delhi #Face Cancer Doctor

0 notes

amith9 · 4 years

Text

Paraganglioma Treatment Market is Booming Market to Grow at Healthy CAGR forecast by 2026

The Paraganglioma Treatment Market research report is a stunning aide for an imperative thought, improved fundamental authority and better business frameworks. The report joins estimations of the ongoing state of the market, CAGR values, market size and overall industry share, income age and significant changes required later on items. The Paraganglioma Treatment Market report has information and data as graphs, tables and outlines that can be adequately understood by the associations. The market thinks about, bits of learning and investigation joined into this overall Paraganglioma Treatment Market report keeps business focus indisputably into the concentration with which you can reach to the business objectives.

Market Analysis:

Influencing players of this market are:

Few of the major competitors currently working in the global paraganglioma treatment market are Progenics Pharmaceuticals, Inc, AstraZeneca, Advanced Accelerator Applications, Jubilant Life Sciences Ltd, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Cipla Inc, Amneal Pharmaceuticals LLC, Amerigen Pharmaceuticals Limited, Jiangsu Hengrui Medicine Co., Ltd, Fresenius Kabi AG, ONO PHARMACEUTICAL CO., LTD and others.

Get Exclusive Sample Copy of this Report@

https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-paraganglioma-treatment-market

This Paraganglioma Treatment Market report consolidates comprehensive industry examination with exact data and conjectures that offers total research arrangements and brings the most extreme industry clarity for decision making.

Analysis based on various segments-:

This analysis gives an examination of various segments that are relied upon to witness the quickest development amid the estimated forecast frame.

And this is done on the basis of-:

By Type

Sympathetic Paragangliomas

Parasympathetic Paragangliomas

By Site of Origin

Caroid Paragangliomas

Cervical Paragangliomas

Vagal Paragangliomas

Others

By Therapy Type

Radiation Therapy

Chemotherapy

Peptide Receptor Radionuclide Therapy (PRRT)

Others

By Treatment

Medication

Surgery

By Drugs

Iobenguane I 131

Cyclophosphamide

Vincristine

Dacarbazine

Others

By Route of Administration

Oral

Injectable

By End Users

Hospitals

Homecare

Specialty Clinics

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Others

By Geography

North America

South America

Europe

Asia-Pacific

Middle East & Africa

Canada

Mexico

Brazil

Rest of South America

Germany

France

United Kingdom

Italy

Spain

Russia

Turkey

Belgium

Netherlands

Switzerland

Rest of Europe

Japan

China

South Korea

India

Australia

Singapore

Thailand

Malaysia

Indonesia

Philippines

Rest of Asia Pacific

South Africa

Rest of Middle East & Africa

Regional Insights-

Regional analysis helps the market players to take an exhaustive assessment of the Paraganglioma Treatment Market region wise so that it becomes easy for them to distinguish and investigate the developing pattern and hidden opportunities all over the world.

The Paraganglioma Treatment Market covers regions such as- South America, North America, Europe, Asia-Pacific, Middle East, and Africa.

Get Detailed TOC@

https://www.databridgemarketresearch.com/toc/?dbmr=global-paraganglioma-treatment-market

Analysis based on Competition-:

The Paraganglioma Treatment Market report presents profiles of key market players and information about different techniques they have utilized, for example, new product dispatches, extensions, understandings, joint endeavors, associations, acquisitions, and others to expand their impressions in this market so as to continue in long run.

Key queries addressed in this report-:

What will be the market size and market share in the upcoming future?

What are the new and hidden opportunities in the market?

Who are the top players in market?

How the challenge goes later on?

Which are the main regions impacting the market growth?

What are the difficulties in future?

Key Issues addressed here-:

Uncertainty of upcoming revenue pockets and growth areas.

Understanding business sector sentiments.

Understanding the most dependable venture focuses.

Competitiveness of Top industry players

Trending factors which are impacting the market growth.

Challenges and threats faced by the leading players

Research strategies and tools used-:

This Paraganglioma Treatment Market research report helps the readers to know about the overall market scenario, strategy to further decide on this market project. It utilizes SWOT analysis, Porter’s Five Forces Analysis and PEST analysis.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [email protected]

Report Related :

paresthesia market

pharmaceutical equipment testing market

plexopathy treatment market

#Paraganglioma Treatment #Paraganglioma Treatment share #Paraganglioma Treatment size #Paraganglioma Treatment trends #Paraganglioma Treatment anlysis #Paraganglioma Treatment overview #Paraganglioma Treatment type #Paraganglioma Treatment report #Paraganglioma Treatment research #Paraganglioma Treatment market #Paraganglioma Treatment insight #Paraganglioma Treatment application #.

0 notes

healthcare-market · 3 years

Text

Radiopharmaceutical Theranostics Market Key Players, Industry Overview and Forecast Analysis

Radiopharmaceutical Theranostics Market: Introduction

Request a PDF Brochure- https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82604

Rise in Prevalence of Cancer to Drive Global Market

Request for Analysis of COVID19 Impact on Radiopharmaceutical Theranostics Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=82604

Lutetium (Lu) 177 to Dominate Global Market

Oncology to Offer Lucrative Opportunities

High Number of Cyclotrons Facilities to Drive Global Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=82604

Targeted Therapeutic (Rx) to be Promising Segment

Hospitals to be Major End Users

North America to Lead Radiopharmaceutical Theranostics Market

Buy now Radiopharmaceutical Theranostics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=82604&ltype=S

Competition Landscape

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/increase-in-demand-for-new-therapies-for-effective-management-to-drive-global-menopausal-hot-flashes-treatment-market-says-tmr-301378552.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com

0 notes